Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.19.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents [note 8] $ 9,515 $ 5,284
Restricted cash [note 8 and 14]   222
Short-term investments [note 8] 5,089  
Amounts receivable 7 9
Prepaid expenses 926 393
Total current assets 15,537 5,908
Restricted cash [note 8] 50 50
Property and equipment, net [note 9] 35 59
Other assets [note 10] 118 309
License agreement [note 2, 5, 6 and 7] 2,310 2,532
Goodwill [note 2 and 6] 1,034 1,034
Total assets 19,084 9,892
Current liabilities:    
Accounts payable 144 213
Accrued liabilities other 748 438
Accrued clinical liabilities 1,199 877
Accrued compensation 1,168 458
Current portion of long-term obligations [note 14] 11 27
Total current liabilities 3,270 2,013
Long-term obligations [note 14] 12  
Total liabilities 3,282 2,013
Commitments and contingencies [note 14]
Stockholders' equity:    
Series A convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, 579 issued and outstanding at December 31, 2018 and zero issued and outstanding at December 31, 2017.
Common stock, $0.001 par value, 150,000,000 shares authorized, 6,721,117 and 1,195,675 issued at December 31, 2018 and December 31, 2017, respectively, and 6,721,117 and 1,194,793 outstanding at December 31, 2018 and December 31, 2017, respectively 18 12
Additional paid-in capital 41,161 20,556
Accumulated deficit (25,381) (12,694)
Accumulated other comprehensive income 4 5
Total stockholders' equity 15,802 7,879
Total liabilities and stockholders' equity $ 19,084 $ 9,892